Year: 2016

Date Title
Dec 27, 2016 Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD
Dec 23, 2016 Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy
Dec 20, 2016 Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
Dec 13, 2016 United States Congress Passes Bill that Represents a Major Opportunity for Regenerative Therapies
Dec 06, 2016 Pluristem’s PLX-R18 Advances into Second Cohort of Dose Selection Study for Treatment of Acute Radiation Syndrome
Nov 15, 2016 Pluristem Reports First Quarter Fiscal 2017 Corporate and Financial Highlights
Nov 10, 2016 Pluristem’s $30 Million Equity Funding Approved by Innovative Medical Management Co.’s Shareholders
Nov 07, 2016 Pluristem Continues to Strengthen its Position in China and Receives Key Cell Therapy Patent
Nov 01, 2016 Pluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency
Oct 25, 2016 Pluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a Leading Institutional Life Sciences Fund
Oct 13, 2016 Pluristem CEO Zami Aberman Re-Elected to Alliance for Regenerative Medicine’s Board of Directors
Sep 14, 2016 Pluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator
Sep 12, 2016 Pluristem Provides Fiscal Year 2016 Corporate and Financial Highlights
Sep 08, 2016 Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular Medicine
Aug 09, 2016 Pluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program
Aug 02, 2016 Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia
Jul 27, 2016 Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture
Jul 20, 2016 Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID
Jul 11, 2016 Pluristem Advances its U.S. FDA Trial in Hematologic Indication
Jun 22, 2016 Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy
May 16, 2016 Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
May 10, 2016 Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
May 09, 2016 Pluristem Awarded $3.3 Million Grant by Israeli Government
Apr 21, 2016 Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke
Apr 13, 2016 Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents
Feb 16, 2016 National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome
Feb 10, 2016 Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
Jan 26, 2016 Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016
Jan 12, 2016 Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant
Jan 06, 2016 New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates their Superiority over other cells